Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach?
Delayed oophorectomy
High-grade serous cancer
Ovarian cancer
Risk-reducing surgery
Salpingectomy
Journal
Journal of minimally invasive gynecology
ISSN: 1553-4669
Titre abrégé: J Minim Invasive Gynecol
Pays: United States
ID NLM: 101235322
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
25
08
2020
accepted:
28
09
2020
pubmed:
11
10
2020
medline:
8
6
2021
entrez:
10
10
2020
Statut:
ppublish
Résumé
To summarize published evidence supporting current strategies for the prevention of epithelial ovarian cancer in women with a genetic, elevated risk for the development of this disease, as well as the emerging data on the novel salpingectomy with delayed oophorectomy (SDO) strategy. Furthermore, we will explore whether salpingectomy alone is a viable risk-reducing strategy for these women. We will also discuss current national guidelines for risk-reducing surgery based on patients' individual genetic predisposition. MEDLINE, PubMed, EMBASE, and the Cochrane Database, with a focus on randomized controlled trials and large prospective, observational studies. The key search terms for our review included Medical Subject Headings: "salpingectomy," "ovarian cancer," and "risk-reducing surgery." The fallopian tube is now well established as the site of origin for most ovarian cancers, particularly high-grade serous carcinomas. This finding has led to the development of new preventive surgical techniques, such as SDO, which may be associated with fewer side effects. However, until the results of ongoing trials are reported and the impact of SDO on ovarian cancer risk reduction is established, it should not be recommended outside of clinical trials, and bilateral salpingo-oophorectomy remains the treatment of choice for risk-reducing surgery, especially in women with a genetic, high risk for ovarian cancer. The decision to undergo risk-reducing surgery among women with an elevated risk for ovarian cancer should be made after comprehensive consultation and individually based on genetic predisposition, childbearing status, and personal preference.
Identifiants
pubmed: 33038519
pii: S1553-4650(20)31082-7
doi: 10.1016/j.jmig.2020.09.020
pmc: PMC7954812
mid: NIHMS1635843
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
403-408Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2020 AAGL. Published by Elsevier Inc. All rights reserved.
Références
JAMA. 2011 Jun 8;305(22):2295-303
pubmed: 21642681
Lancet. 2019 Sep 28;394(10204):1159-1168
pubmed: 31474332
N Engl J Med. 2002 May 23;346(21):1616-22
pubmed: 12023993
J Clin Oncol. 2008 Mar 10;26(8):1331-7
pubmed: 18268356
Am J Obstet Gynecol. 1999 Mar;180(3 Pt 2):S312-6
pubmed: 10076170
Lancet Oncol. 2006 Oct;7(10):821-8
pubmed: 17012044
BMC Cancer. 2015 Aug 19;15:593
pubmed: 26286255
JAMA Oncol. 2016 Apr;2(4):482-90
pubmed: 26720728
Maturitas. 2010 Jul;66(3):310-4
pubmed: 20409655
BJOG. 2017 Jan;124(2):314-320
pubmed: 27342222
Maturitas. 2011 Nov;70(3):261-5
pubmed: 21893388
N Engl J Med. 2002 May 23;346(21):1609-15
pubmed: 12023992
J Reprod Med. 2001 Mar;46(3 Suppl):317-24
pubmed: 11304879
Genet Med. 2008 Mar;10(3):161-166
pubmed: 18344704
Cancers (Basel). 2020 Jul 17;12(7):
pubmed: 32708835
Gynecol Oncol. 2013 Jun;129(3):448-51
pubmed: 23558052
Am J Surg Pathol. 2007 Feb;31(2):161-9
pubmed: 17255760
Gynecol Oncol. 2019 Nov;155(2):280-282
pubmed: 31522838
Obstet Gynecol. 2013 Jan;121(1):14-24
pubmed: 23232752
Mod Pathol. 2017 May;30(5):710-721
pubmed: 28106106
J Clin Oncol. 2014 May 20;32(15):1547-53
pubmed: 24567435
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
J Natl Compr Canc Netw. 2017 Jan;15(1):9-20
pubmed: 28040716
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Gynecol Oncol. 2018 Jul;150(1):79-84
pubmed: 29735278
Am J Epidemiol. 2002 Aug 15;156(4):363-73
pubmed: 12181107
JAMA. 2010 Sep 1;304(9):967-75
pubmed: 20810374
J Natl Cancer Inst. 2009 Jan 21;101(2):80-7
pubmed: 19141781
Obstet Gynecol. 2015 Feb;125(2):338-345
pubmed: 25568991
Hum Mutat. 2018 May;39(5):593-620
pubmed: 29446198
Gynecol Oncol. 2019 Feb;152(2):426-433
pubmed: 30503267
BJOG. 2017 May;124(6):872-878
pubmed: 28218502
Gynecol Oncol. 2014 May;133(2):283-6
pubmed: 24582866
Cancers (Basel). 2018 Nov 28;10(12):
pubmed: 30486509
Menopause. 1998 Fall;5(3):189-90
pubmed: 9774766
Am J Hum Genet. 2001 Mar;68(3):700-10
pubmed: 11179017
Am J Obstet Gynecol. 2014 May;210(5):471.e1-11
pubmed: 24412119
Gynecol Oncol. 2015 Feb;136(2):305-10
pubmed: 25560807
Am J Hum Genet. 2003 May;72(5):1117-30
pubmed: 12677558
J Natl Cancer Inst. 2015 Jan 27;107(2):
pubmed: 25628372
Cancer. 2005 Dec 15;104(12):2807-16
pubmed: 16284991
Gynecol Oncol. 2017 Dec;147(3):705-713
pubmed: 29054568
Gynecol Oncol. 2011 Apr;121(1):163-8
pubmed: 21216453